Function of Axl receptor tyrosine kinase in non-small cell lung cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Oncology Letters

• Publication date

  2017-12-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/ol.2017.7694PMID 29434997PMCID PMC5778882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Axl Receptor Axis: A New Therapeutic Target in Lung Cancer

  2016cited by this paper
• AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity

  2016cited by this paper
• Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like Cells

  2015cited by this paper
• AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.

  2015cited by this paper
• The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung

  2015cited by this paper
• AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

  2015cited by this paper
• Axl activates autocrine transforming growth factor‐β signaling in hepatocellular carcinoma

  2015cited by this paper
• Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer

  2015cited by this paper
• Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas.

  2015cited by this paper
• EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer

  2015cited by this paper
• EMT is not required for lung metastasis but contributes to chemoresistance

  2015cited by this paper
• TAM receptor signaling in immune homeostasis.

  2015cited by this paper
• AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells

  2015cited by this paper
• Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma

  2015cited by this paper
• Insights into the roles of hnRNP A2/B1 and AXL in non-small cell lung cancer.

  2015cited by this paper
• The insulin‐like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild‐type epidermal growth factor receptor

  2014cited by this paper
• Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

  2014cited by this paper
• Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities

  2014cited by this paper
• Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer

  2014cited by this paper
• The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications

  2014cited by this paper
• AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.

  2014cited by this paper
• AXL mediates resistance to cetuximab therapy.

  2014cited by this paper
• AXL kinase as a novel target for cancer therapy

  2014cited by this paper
• The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer

  2014cited by this paper
• Protumoral effect of macrophage through Axl activation on mucoepidermoid carcinoma.

  2014cited by this paper
• Axl Phosphorylates Elmo Scaffold Proteins To Promote Rac Activation and Cell Invasion

  2014cited by this paper
• Imaging Axl expression in pancreatic and prostate cancer xenografts.

  2014cited by this paper
• The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.

  2014cited by this paper
• Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

  2014cited by this paper
• Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma.

  2014cited by this paper
• Receptor Tyrosine Kinases, TYRO3, AXL, and MER, Demonstrate Distinct Patterns and Complex Regulation of Ligand-induced Activation*

  2014cited by this paper
• Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism.

  2013cited by this paper
• Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients.

  2013cited by this paper
• The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells

  2013cited by this paper
• First Axl inhibitor enters clinical trials

  2013cited by this paper
• AXL induces epithelial to mesenchymal transition and regulates the function of breast cancer stem cells

  2013cited by this paper
• Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

  2013cited by this paper
• Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

  2013cited by this paper
• Cisplatin influences acquisition of resistance to molecular‐targeted agents through epithelial–mesenchymal transition‐like changes

  2013cited by this paper
• Epithelial‐mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4‐ALK translocation

  2013cited by this paper
• Axl is essential for VEGF‐A‐dependent activation of PI3K/Akt

  2012cited by this paper
• Growth arrest-specific gene 6 (gas6) and vascular hemostasis.

  2012cited by this paper
• Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer

  2012cited by this paper
• Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

  2012cited by this paper
• Galectin‐3 is a new MerTK‐specific eat‐me signal

  2012cited by this paper
• Higher Expression of Receptor Tyrosine Kinase Axl, and Differential Expression of its Ligand, Gas6, Predict Poor Survival in Lung Adenocarcinoma Patients

  2012cited by this paper
• An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

  2012cited by this paper
• Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members.

  2011cited by this paper
• TAM receptors in leukemia: expression, signaling, and therapeutic implications.

  2011cited by this paper
• Targeting Axl and Mer Kinases in Cancer

  2011cited by this paper
• Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

  2010cited by this paper
• R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

  2010cited by this paper
• Tubby and tubby‐like protein 1 are new MerTK ligands for phagocytosis

  2010cited by this paper
• Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

  2009cited by this paper
• Epithelial-mesenchymal transitions in development and disease.

  2009cited by this paper
• Targeting the mTOR signaling network for cancer therapy.

  2009cited by this paper
• TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

  2008cited by this paper
• Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia.

  2008cited by this paper
• Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1

  2008cited by this paper
• Immunobiology of the TAM receptors

  2008cited by this paper
• A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

  2007cited by this paper
• Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL.

  2007cited by this paper
• Gas6 and protein S

  2006cited by this paper
• Structural basis for Gas6–Axl signalling

  2006cited by this paper
• Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases.

  2006cited by this paper
• Induction of Gas6 protein in CCl4‐induced rat liver injury and anti‐apoptotic effect on hepatic stellate cells

  2006cited by this paper
• Expression of axl in lung adenocarcinoma and correlation with tumor progression.

  2005cited by this paper
• Expression of the Proto-Oncogene Axl in Renal Cell Carcinoma

  2003cited by this paper
• Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis

  2002cited by this paper
• Novel Mechanism for Gonadotropin-Releasing Hormone Neuronal Migration Involving Gas6/Ark Signaling to p38 Mitogen-Activated Protein Kinase

  2002cited by this paper
• Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis

  2001cited by this paper
• Gas6 Induces Mesangial Cell Proliferation via Latent Transcription Factor STAT3*

  2001cited by this paper
• Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells.

  2001cited by this paper
• Expression of the receptor protein‐tyrosine kinases Tyro‐3, Axl, and Mer in the developing rat central nervous system

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• The Gas6/Axl system: a novel regulator of vascular cell function.

  1999cited by this paper
• Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site

  1997cited by this paper
• Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase

  1996cited by this paper
• Identification of the Product of Growth Arrest-specific Gene 6 as a Common Ligand for Axl, Sky, and Mer Receptor Tyrosine Kinases*

  1996cited by this paper
• The Transforming Receptor Tyrosine Kinase, Axl, Is Post-translationally Regulated by Proteolytic Cleavage (*)

  1995cited by this paper
• The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases.

  1995cited by this paper
• Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6

  1995cited by this paper
• Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis.

  1994cited by this paper
• The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade

  1993cited by this paper
• axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase

  1991cited by this paper
• A novel putative tyrosine kinase receptor with oncogenic potential.

  1991cited by this paper
• Transforming genes in chronic myelogenous leukemia.

  1988cited by this paper
• Genes specifically expressed at growth arrest of mammalian cells.

  1988cited by this paper

• A Multikinase Inhibitor AX-0085 Blocks FGFR1 Activation to Overcomes Osimertinib Resistance in Non-Small Cell Lung Cancer

  2025cites this paper
• Calumenin, A Calcium‐Binding Modulatory Protein, Effective in Pathological Calcifications and Cancers, With Therapeutic Application Promise

  2025cites this paper
• Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress.

  2025cites this paper
• Shedding Phosphorylated Axl Receptor in Lung Adenocarcinoma: Dual-Domain Immunohistochemistry Approach

  2025cites this paper
• Prospects of current AXL-targeting therapies in early phase cancer trials

  2025cites this paper
• Recent advances in TAM mechanisms in lung diseases

  2025cites this paper
• Nanoparticle-Mediated Cosilencing of Drug Resistance and Compensatory Genes Enhances Lung Cancer Therapy.

  2025cites this paper
• Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer

  2025cites this paper
• Biomarkers in Immunology: Their Impact on Immune Function and Response

  2025cites this paper
• AXL kinase inhibitor exhibits antitumor activity by inducing apoptotic cell death in triple-negative breast cancer cells.

  2025cites this paper
• The role of tumor-associated macrophages in lung cancer

  2025cites this paper
• Role of STAT3 in cancer cell epithelial-mesenchymal transition (Review)

  2024cites this paper
• Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.

  2024cites this paper
• AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies

  2024cites this paper
• Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers

  2024cites this paper
• Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

  2024cites this paper
• Identification of a novel DNA repair inhibitor using an in silico driven approach shows effective combinatorial activity with genotoxic agents against multidrug‐resistant Escherichia coli

  2024cites this paper
• AXL transcriptionally up-regulates TMEM14A expression to mediate cell proliferation in non-small-cell lung cancer cells.

  2023cites this paper
• AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers.

  2023cites this paper
• Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis

  2023cites this paper
• Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells

  2022cites this paper
• Integrated proteomics-based physical and functional mapping of AXL kinase signaling pathways and inhibitors define its role in cell migration.

  2022cites this paper
• 肿瘤相关巨噬细胞在肺癌中的研究进展

  2022cites this paper
• Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

  2022cites this paper
• The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges

  2022cites this paper
• Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors

  2022cites this paper
• Bioluminescent RAPPID Sensors for the Single-Step Detection of Soluble Axl and Multiplex Analysis of Cell Surface Cancer Biomarkers

  2022cites this paper
• βIII‐tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c‐Met positive non‐small cell lung cancer cells

  2022cites this paper
• AXL kinase inhibitors- A prospective model for medicinal chemistry strategies in anticancer drug discovery.

  2022cites this paper
• Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model

  2022cites this paper
• Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro

  2022cites this paper
• The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications

  2021cites this paper
• SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models

  2021cites this paper
• Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma

  2021cites this paper
• RNA-based therapies: A cog in the wheel of lung cancer defense

  2021cites this paper
• 20 (S)-ginsenoside Rh2 inhibits colorectal cancer cell growth by suppressing the Axl signaling pathway in vitro and in vivo

  2021cites this paper
• Accelerating AXL targeting for TNBC therapy.

  2021cites this paper
• A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications

  2021cites this paper
• Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.

  2021cites this paper
• Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.

  2021cites this paper
• Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors

  2020influential citation
• Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma

  2020cites this paper
• Astragalus Polysaccharide (PG2) Suppresses Macrophage Migration Inhibitory Factor and Aggressiveness of Lung Adenocarcinoma Cells.

  2020cites this paper
• Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer

  2020cites this paper
• Immunological role of TAM receptors in the cancer microenvironment.

  2020cites this paper
• A review on RNAi therapy for NSCLC: Opportunities and challenges.

  2020cites this paper
• Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression

  2019cites this paper
• Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.

  2019cites this paper
• Antibody-drug conjugates for lung cancer in the era of personalized oncology.

  2019cites this paper
• Downregulation of fibroblast growth factor 5 inhibits cell growth and invasion of human nonsmall‐cell lung cancer cells

  2018cites this paper
• The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview

  2018cites this paper
• Studying macro-and microvascular responses to major surgery to develop preventive strategies for perioperative complications

  year unknowncites this paper